Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea

Infection

Volumn 41, Issue 3, 2013, Pages 603-612

  Kim, B ^a   Kim, J ^a   Seo, M R ^a   Wie, S H ^b   Cho, Y K ^c   Lim, S K ^d   Lee, J S ^e   Kwon, K T ^f   Lee, H ^g   Cheong, H J ^h   Park, D W ⁱ   Ryu, S Y ^j   Chung, M H ^k   Ki, M ^l   Pai, H ^a  

^a Hanyang University   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Gachon University   (South Korea)

^d Ajou University Medical CentSuwon   (South Korea)

^e Hallym University   (South Korea)

^f Daegu Fatima Hospital   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ Korea University   (South Korea)

^j Keimyung University   (South Korea)

^k Inha University Hospital   (South Korea)

^l Eulji University   (South Korea)

more..

Author keywords

Community acquired; Extended spectrum lactamase; Risk factor; Urinary tract infection

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFOXITIN; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMOCILLIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ACUTE PYELONEPHRITIS; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATION; BLADDER CATHETERIZATION; CLINICAL FEATURE; COMMUNITY ACQUIRED ACUTE PYELONEPHRITIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ENTEROBACTER; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCUS; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTILOCUS SEQUENCE TYPING; PROSPECTIVE STUDY; PROTEUS; PSEUDOMONAS AERUGINOSA; SOUTH KOREA; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BETA-LACTAMASES; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PROSPECTIVE STUDIES; PYELONEPHRITIS; REPUBLIC OF KOREA; RISK FACTORS;

EID: 84878866083     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0441-z     Document Type: Article

References (25)

1. Nicolle LE. Urinary tract infection: traditional pharmacologic therapies. Am J Med. 2002;113(Suppl 1A):35S-44S. pii: S0002934302010586.
2. Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2010;36:284-7. pii: S0924-8579(10)00227-X.
3. Kang CI, Cheong HS, Chung DR, Peck KR, Song JH, Oh MD, et al. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Eur J Clin Microbiol Infect Dis. 2008;27:85-8. doi: 10.1007/s10096-007-0401-6.
4. Pitout JDD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159-66. doi: 10.1016/S1473-3099(08)70041-0.
5. Shin J, Kim DH, Ko KS. Comparison of CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia. J Infect. 2011;63:39-47. doi: 10.1016/j.jinf.2011.05.003.
6. Cantón R, González-Alba JM, Galán JC. CTX-M enzymes: origin and diffusion. Front Microbiol. 2012;3:110. doi: 10.3389/fmicb.2012. 00110.
7. Lee DS, Lee CB, Lee SJ. Prevalence and risk factors for extended spectrum beta-lactamase-producing uropathogens in patients with urinary tract infection. Korean J Urol. 2010;51:492-7. doi: 10.4111/kju.2010.51.7.492.
8. Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012;18:169-75. doi: 10.1089/mdr.2011.0139.
9. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006;57:780-3. pii: dkl035.
10. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-7. doi: 10.1086/420816. pii: CID30647.
11. Colodner R, Kometiani I, Chazan B, Raz R. Risk factors for community-acquired urinary tract infection due to quinolone-resistant E. coli. Infection. 2008;36:41-5. doi: 10.1007/s15010-007-7083-y.
12. Sotto A, De Boever CM, Fabbro-Peray P, Gouby A, Sirot D, Jourdan J. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol. 2001;39:438-44. doi: 10.1128/JCM.39.2.438-444.2001.
13. Mathew A, Harris AM, Marshall MJ, Ross GW. The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J Gen Microbiol. 1975;88:169-78.
14. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother. 2010;65:490-5. pii: dkp498.
15. Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum (beta)-lactamases. J Antimicrob Chemother. 2006;57:154-5. pii: dki412.
16. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother. 2009;53:2733-9. pii: AAC.00297-09.
17. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 19th informational supplement. CLSI document M100-S19. Wayne: CLSI; 2009.
18. Azap OK, Arslan H, Serefhanoǧlu K, Colakoǧlu S, Erdoǧan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16:147-51. pii: CLM2941.
19. Rajagopalan S. Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis. 2005;40:990-6. pii: CID30319.
20. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli. Antimicrob Agents Chemother. 2010;54:4006-8. pii: AAC.01760-09.
21. Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333-40. doi: 10.1007/s15010-011-0132-6.
22. Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002;46:1481-91.
23. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect. 2002;52:99-106. pii: S0195670102912880.
24. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682-90. doi: 10.1086/604713.
25. Du B, Long Y, Liu H, Chen D, Liu D, Xu Y, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med. 2002;28:1718-23. doi: 10.1007/s00134-002-1521-1.